Commentary|Videos|April 17, 2026

Oncology PulsePoints: ASCO WBC Growth Factors Guidelines Update

Author(s)Alexandra Gerlach, Content Producer, Ryu Kariyawasam-Chavez, Content Associate, Amber B. Clemmons, PharmD, BCOP, FHOPA

Fact checked by: Nicole Canfora Lupo

Amber Clemmons PharmD, BCOP, FHOPA, highlights key changes in evidence grading, shared decision-making, and dosing strategies in neutropenia management.

The use of white blood cell (WBC) growth factors in oncology has continued to evolve alongside expanding evidence supporting individualized approaches to neutropenia prevention and management. The latest guideline update from the American Society of Clinical Oncology (ASCO) reflects nearly a decade of new data since its last revision in 2015, incorporating updated evidence grading, expanded guidance on shared decision-making, and greater flexibility in dosing and administration strategies.